Yumetra

Company Overview

Snapshot

Founded in April 2021 by Gilad Agmon and Eli Pinthus, Yumetra operates with 1–10 employees. The company has secured funding across two rounds from Fresh Start, and holds a patent. In March 2026, Yumetra raised a Pre-Seed round.

Business overview

Yumetra develops functional food products and plant-derived bioactives aimed at supporting oral health and providing proactive wellness interventions. The company's core offering, Cinnovir, is a patented botanical extract derived through advanced fractionation and formulation. By integrating these bioactives into everyday food formats, Yumetra addresses health at the oral environment, bypassing traditional medical delivery systems and minimizing changes to consumer behavior. The company operates within the Agriculture & Food Technologies sector, specifically in Food Tech, focusing on Novel Food & Ingredients and Food Processing.

Strategic signal

In April 2026, Yumetra was featured in a Maariv article highlighting strategic innovation collaborations by the Wingate Institute. This signals growing recognition and potential for partnerships within the Israeli innovation ecosystem, suggesting a validation of Yumetra's approach to integrating plant-based bioactives into functional foods and its relevance to broader wellness initiatives.

Company Intelligence Q&A

What is Yumetra's primary focus?

Yumetra focuses on developing functional food products and plant-derived bioactives to support oral health and provide proactive wellness interventions.

What is Cinnovir?

Cinnovir is Yumetra's patented botanical extract, produced through advanced fractionation and formulation techniques, designed for integration into functional foods.

What is the strategic significance of Yumetra's approach?

Yumetra's strategic approach involves integrating bioactives into everyday food formats, addressing health at the oral environment without requiring significant changes to consumer behavior, thus making wellness more accessible and seamless.